Implementation of AMNOG: An industry perspective.

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Regulatory Science

Background:

• Germany enacted the Arzneimittelmarktneuordnungsgesetz (AMNOG) in 2010, regulating pharmaceutical products launched after January 1, 2011.
• AMNOG establishes a two-phase process for determining reimbursement prices: benefit assessment and price negotiation.

Purpose of the Study:

• To investigate the requirements for benefit assessment of new medicinal products under Germany's AMNOG law.
• To critically examine the methods used by German authorities in the initial benefit assessment phase.
• To propose alternative approaches for specific aspects of the benefit assessment process.

Main Methods:

• Analysis of the benefit assessment process mandated by AMNOG.
• Focus on key methodological aspects: comparator selection, patient-relevant endpoints, subgroup analyses, benefit extent, net benefit determination, endpoint definitions, and uncertainty quantification.
• Development of alternative methodological suggestions.

Main Results:

• The study details the stringent requirements for assessing the additional benefit of new drugs against appropriate comparators (zweckmäßige Vergleichstherapie, zVT).
• It highlights challenges and potential limitations in current methodologies concerning endpoint selection, subgroup analysis, and benefit quantification.
• Alternative approaches are proposed for specific methodological issues encountered in the benefit assessment process.

Conclusions:

• The benefit assessment phase under AMNOG is crucial for establishing the value of new pharmaceuticals.
• Refinements in methodological approaches, particularly regarding comparator choice and endpoint relevance, are needed.
• Further research and collaboration are invited to develop robust solutions for optimizing benefit assessment and ensuring fair reimbursement.